The state of Massachusetts currently has 3 active clinical trials seeking participants for Hepatitis B research studies. These trials are conducted in various cities, including Boston, Worcester, Springfield and Burlington.
Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
Recruiting
The study aims to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both CHB and HIV who have been receiving suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening. The study will also evaluate if TLR8 stimulation with SLGN will reduce hepatitis B surface antigen (HBsAg) titers in the blood.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/17/2024
Locations: Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts
Conditions: Hepatitis B, HIV Infections
National Liver Cancer Screening Trial
Recruiting
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible patients will be randomized in a 1:1 fashion to Arm A using semi-annual ultrasound and AFP-based screening or Arm B using semi-annual screening using GALAD alone. Randomization will be stratified by sex, enrolling site, Child Pugh class (A vs. B), an... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
03/27/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Carcinoma, Hepatocellular, Liver Cancer, Liver Cirrhosis, Hepatitis B
Long-term Follow-up Study to Evaluate Durability of Sustained Virologic Response (SVR) in Previous GSK3228836 Study Participants (B-Sure)
Recruiting
This is a long-term follow-up study to assess durability of efficacy, as measured by SVR, in participants who have received prior treatment with GSK3228836 and achieved a complete or partial response. No further treatment with GSK3228836 will be administered in this study.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/06/2023
Locations: GSK Investigational Site, Boston, Massachusetts
Conditions: Hepatitis B